Inoviv, a London, UK-based biomarker development company, raised an undisclosed amount in funding.
Backers from Hoxton Ventures and Foresight Group.
The company intends to use the funds to further expand its commercial activities to support the pharmaceutical and biotech space in support of clinical proteomics, including clinical trial monitoring, while also extending R&D capacity and innovation to address the biomarker market, and accelerate the development and approval of life-changing therapeutics.
Led by CEO Michael Dove, Inoviv offers solutions in hybrid assays to allow multiplexing of previously immeasurable biomarkers and rapid standards development to support quantitative workflows. These panels can measure 50+ fully calibrated and validated, definitive biomarkers per sample covering a range of analytes across different sample types that are highly reproducible. Assays can be tailored according to the drug, disease, and mechanism of action, and are carried out in GLP/GCP accredited laboratories.
Commenting on the news, Michael Dove said “We are delighted to announce this investment from Hoxton Ventures and Foresight Group. There has never been a more pressing need for technologies that can deliver definitive, fully quantitative data to accelerate clinical development and regulatory approval. This funding represents a significant milestone in Inoviv’s journey and will allow us to grow the capacity we need to deliver on the promise of precision biomarkers for the global pharmaceutical research community.”
FinSMEs
30/01/2024